Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axicabtagene Ciloleucel + Utomilumab in Relapsed/Refractory Large B-Cell Lymphoma
NCT03704298Phase 1Terminated
- Sponsor
- Kite Pharma
- Start
- Nov 2018
- Primary completion
- May 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of utomilumab in diffuse large B-cell lymphoma (DLBCL) (6 arms), sponsored by Kite Pharma. Primary endpoints: Percentage of Participants Experiencing Adverse Events Defined as Dose Limiting Toxicities at 28 days and Complete Response Rate at 1 year. Started Nov 2018; status: terminated.
02
Drugs
utomilumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03704298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03704298.